BiotechTube

HSK21542 + Placebo + morphine

Phase 3Recruiting
0 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postoperative Pain Management

Conditions

Postoperative Pain Management

Trial Timeline

Jul 28, 2025 → Mar 1, 2026

NCT ID
NCT07186426

About HSK21542 + Placebo + morphine

HSK21542 + Placebo + morphine is a phase 3 stage product being developed by Haisco Pharmaceutical Group for Postoperative Pain Management. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07186426. Target conditions include Postoperative Pain Management.

What happened to similar drugs?

10 of 20 similar drugs in Postoperative Pain Management were approved

Approved (10) Terminated (1) Active (10)
✅Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
🔄SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
✅EsomeprazoleAstraZenecaApproved
🔄MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
✅Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
✅Sugammadex + NeostigmineMerckApproved
🔄MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07186426Phase 3Recruiting

Competing Products

20 competing products in Postoperative Pain Management

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
27
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
43
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
42
Ondansetron + PalonosetronEisaiPhase 2
35
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2/3
38
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
28
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
28
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
29
EsomeprazoleAstraZenecaApproved
43
deep neuromuscular blockMerckPre-clinical
26
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
35
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
40
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
43
MK0719MerckPhase 2
27
Sugammadex + NeostigmineMerckApproved
43
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
40